CANCER
1PMPyU0
1PMPyU0
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Bloodwise 6<br />
Report of the Trustees for the year ended 31 March 2015<br />
Achieving our vision<br />
Every 14 minutes someone in the UK is diagnosed<br />
with blood cancer or a related disorder. That’s almost<br />
38,000 people every year. Although blood cancer<br />
research is one of the most advanced and innovative<br />
parts of science, the fact that there are more than 100<br />
different types of blood cancer makes our job a very<br />
complex one.<br />
ALL HAEMATOLOGICAL<br />
NEOPLASM<br />
EXPECTED NO.<br />
OF CASES<br />
Total 37,990<br />
Although blood cancers mainly affect people over<br />
50, they’re unusual because they can affect anyone<br />
regardless of age and lifestyle.<br />
And because there are so many types of blood cancer,<br />
it’s often not recognised that together they are the<br />
third biggest cancer killer in the UK.<br />
Thanks to research, significant progress has been<br />
made. Today, two thirds of everyone diagnosed with<br />
blood cancer or related pre-cancerous condition will<br />
still be with us in five years’ time. When we started,<br />
very few survived for this long.<br />
There have been many successes. The transformation<br />
in survival for the most common form of childhood<br />
leukaemia from zero in 1960 to 92% (for those taking<br />
part in the latest clinical trials) today; the development<br />
of the first magic bullet therapies in chronic myeloid<br />
leukaemia; the use of monoclonal antibodies in<br />
diagnosis and treatment; and more recently the<br />
development of cell based therapies. These are just<br />
some of the achievements to date.<br />
Our vision is to beat blood cancer and our mission is<br />
to stop people from dying of blood cancer; to make<br />
patients’ lives better; and to stop blood cancers from<br />
happening in the first place.<br />
To achieve this we invest in a robust translational<br />
pipeline of research, in patient services that improve<br />
the experience of patients, on acting as a voice for<br />
patients by campaigning and on generating awareness<br />
and income. We also share our learning and work with<br />
others to achieve results more quickly.<br />
With thanks to HMRN for the statistics shown on<br />
this page hmrn.org/statistics/incidence<br />
Bloodwise trading as Leukaemia & Lymphoma Research Company limited by guarantee 738089<br />
Registered charity 216032 (England & Wales) SC037529 (Scotland)